Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Laif is a branded herbal medicinal product containing standardized dry extract of Hypericum perforatum (St. John’s wort), used primarily for the treatment of mild to moderate depressive episodes and, in some formulations, associated anxiety symptoms. It acts as a multi‑target central nervous system modulator: key constituents such as hyperforin and hypericin are thought to inhibit the reuptake of monoamines including serotonin, norepinephrine, and dopamine, modulate glutamatergic and GABAergic neurotransmission, and influence neuroendocrine and neuroinflammatory pathways. Laif is marketed in various oral formulations (typically film‑coated tablets) and is regulated as a phytopharmaceutical, with documented potential for clinically relevant cytochrome P450 and P‑glycoprotein induction leading to numerous drug–drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Laif.